相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Chromosome 1q21 abnormalities in multiple myeloma
Timothy M. Schmidt et al.
BLOOD CANCER JOURNAL (2021)
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies
Maria-Victoria Mateos et al.
HAEMATOLOGICA (2020)
Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis
Ankur Varma et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome
Meera Mohan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib
Chenxing Du et al.
LEUKEMIA & LYMPHOMA (2020)
Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients
Abdullah S. Al Saleh et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications
Daisuke Ogiya et al.
BLOOD (2020)
Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities
Nadine Abdallah et al.
BLOOD ADVANCES (2020)
Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors A Systematic Review and Meta-analysis
Smith Giri et al.
JAMA ONCOLOGY (2020)
Recent advances in cytogenetic characterization of multiple myeloma
Debra Saxe et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2019)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone
Timothy M. Schmidt et al.
BLOOD CANCER JOURNAL (2019)
Prognostic Value of 1q21 Gain in Multiple Myeloma
Dangui Chen et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients
V. Shah et al.
LEUKEMIA (2018)
Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation
Gunjan L. Shah et al.
LEUKEMIA & LYMPHOMA (2017)
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Ajai Chari et al.
BLOOD (2017)
Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis
Emma C. Scott et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
Saad Z. Usmani et al.
BLOOD (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Multiple Myeloma: Diagnosis and Treatment
S. Vincent Rajkumar et al.
MAYO CLINIC PROCEEDINGS (2016)
Multiple myeloma epidemiology and survival: A unique malignancy
Dickran Kazandjian
SEMINARS IN ONCOLOGY (2016)
The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence In Situ Hybridization in Multiple Myeloma
Gang An et al.
CLINICAL CANCER RESEARCH (2015)
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Extramedullary Manifestation in Multiple Myeloma Bears High Incidence of Poor Cytogenetic Aberration and Novel Agents Resistance
Xiaoyan Qu et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value
Gang An et al.
HAEMATOLOGICA (2014)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2014)
Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients
B. Hebraud et al.
LEUKEMIA (2014)
Improved long-term survival in multiple myeloma up to the age of 80 years
S. Y. Kristinsson et al.
LEUKEMIA (2014)
Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma
P. Leif Bergsagel et al.
BLOOD (2013)
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
Kai Neben et al.
BLOOD (2012)
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents
Saad Z. Usmani et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders
Fiona M. Ross et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival
Herve Avet-Loiseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease
Heather Landau et al.
LEUKEMIA & LYMPHOMA (2012)
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3
John D. Shaughnessy et al.
BLOOD (2011)
Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival
Kevin D. Boyd et al.
CLINICAL CANCER RESEARCH (2011)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value
Brian A. Walker et al.
BLOOD (2010)
Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies
M. A. Dimopoulos et al.
LEUKEMIA (2010)
Deletions of CDKN2C in Multiple Myeloma: Biological and Clinical Implications
Paola E. Leone et al.
CLINICAL CANCER RESEARCH (2008)
Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation
Ichiro Hanamura et al.
BLOOD (2006)
A CDK-independent function of mammalian Cks1:: Targeting of SCFSkp2 to the CDK inhibitor p27Kip1
C Spruck et al.
MOLECULAR CELL (2001)
The cell-cycle regulatory protein Cks1 is required for SCFSkp2-mediated ubiquitinylation of p27
D Ganoth et al.
NATURE CELL BIOLOGY (2001)
分享论文
